# Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

> **NCT07668960** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Mianyi Biopharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection

## Interventions

- **DRUG:** BBM-C101

## Key facts

- **NCT ID:** NCT07668960
- **Lead sponsor:** Shanghai Mianyi Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-17
- **Primary completion:** 2029-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07668960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07668960, "Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07668960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*